These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 7900075

  • 1. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.
    Nurmohamed MT, Berckmans RJ, Morriën-Salomons WM, Berends F, Hommes DW, Rijnierse JJ, Sturk A.
    Thromb Haemost; 1994 Nov; 72(5):685-92. PubMed ID: 7900075
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G.
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [Abstract] [Full Text] [Related]

  • 3. Effects of two different doses of hirudin on APTT, determined with eight different reagents.
    Monreal M, Monreal L, Ruiz de Gopegui R, Espada Y, Angles AM, Monasterio J.
    Thromb Haemost; 1995 Feb; 73(2):219-22. PubMed ID: 7792733
    [Abstract] [Full Text] [Related]

  • 4. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
    Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM.
    Thromb Haemost; 1993 Aug 02; 70(2):286-8. PubMed ID: 8236136
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H.
    Thromb Haemost; 1997 May 02; 77(5):911-9. PubMed ID: 9184402
    [Abstract] [Full Text] [Related]

  • 6. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G, Roser M, Nauck M.
    Semin Thromb Hemost; 2002 Oct 02; 28(5):425-30. PubMed ID: 12420237
    [Abstract] [Full Text] [Related]

  • 7. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM, Meeuwisse-Braun J, Bertina RM.
    Thromb Haemost; 1990 Feb 19; 63(1):16-23. PubMed ID: 2339357
    [Abstract] [Full Text] [Related]

  • 8. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S, Preston FE.
    Thromb Haemost; 1996 May 19; 75(5):734-9. PubMed ID: 8725715
    [Abstract] [Full Text] [Related]

  • 9. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E, Cortellaro M, Leonardi P, Corradi A, Ravasi F, Bertocchi F.
    Thromb Haemost; 1996 Mar 19; 75(3):407-11. PubMed ID: 8701398
    [Abstract] [Full Text] [Related]

  • 10. Clinical monitoring of hirudin and direct thrombin inhibitors.
    Nowak G.
    Semin Thromb Hemost; 2001 Oct 19; 27(5):537-41. PubMed ID: 11668425
    [Abstract] [Full Text] [Related]

  • 11. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P, Boutière B, Horellou MH, Trzeciak MC, Samama MM.
    Thromb Haemost; 1998 Jul 19; 80(1):104-8. PubMed ID: 9684794
    [Abstract] [Full Text] [Related]

  • 12. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R, Jacobs C.
    Res Vet Sci; 2001 Apr 19; 70(2):101-8. PubMed ID: 11356088
    [Abstract] [Full Text] [Related]

  • 13. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E, Watton J, Cesmeli S, Barrowcliffe TW, Thomas DP.
    Thromb Haemost; 1991 Apr 08; 65(4):355-9. PubMed ID: 2057916
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
    D'Angelo SV, Gilardoni F, D'Angelo A.
    Thromb Haemost; 1989 Nov 24; 62(3):861-7. PubMed ID: 2531939
    [Abstract] [Full Text] [Related]

  • 15. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB, Martin CA.
    Can J Vet Res; 2000 Apr 24; 64(2):117-22. PubMed ID: 10805251
    [Abstract] [Full Text] [Related]

  • 16. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G, Pascucci C, Cosmi B, Nenci GG.
    Thromb Haemost; 1990 Apr 12; 63(2):204-7. PubMed ID: 2363121
    [Abstract] [Full Text] [Related]

  • 17. Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study.
    Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G.
    Thromb Haemost; 1993 Sep 01; 70(3):386-8. PubMed ID: 8259534
    [Abstract] [Full Text] [Related]

  • 18. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ.
    Can J Cardiol; 1993 Nov 01; 9(9):797-801. PubMed ID: 8281479
    [Abstract] [Full Text] [Related]

  • 19. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays.
    Fey MF, Lang M, Furlan M, Beck EA.
    Thromb Haemost; 1987 Oct 28; 58(3):853-5. PubMed ID: 3481140
    [Abstract] [Full Text] [Related]

  • 20. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
    Sucker C, Zotz RB, Görlinger K, Hartmann M.
    Acta Anaesthesiol Scand; 2008 Mar 28; 52(3):358-62. PubMed ID: 18205897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.